$12.41
0.72[6.16%]
At close: Apr 26
$12.41
0[0.00%]
After Hours: 4:20PM EDT
Stoke Therapeutics
(NASDAQ:STOK)Latest News for Stoke Therapeutics Stock (NASDAQ:STOK)
Stoke Therapeutics Stock (NASDAQ: STOK)
Categories: All
Thursday, April 11, 2024
Friday, April 05, 2024
Thursday, April 04, 2024
- 12 Health Care Stocks Moving In Thursday's After-Market SessionBenzinga Insights - Apr 4, 2024, 4:31PM
- Assessing Stoke Therapeutics: Insights From 6 Financial AnalystsBenzinga Insights - Apr 4, 2024, 10:00AM
- Cantor Fitzgerald Reiterates Overweight on Stoke TherapeuticsBenzinga Newsdesk - Apr 4, 2024, 9:48AM
Thursday, March 28, 2024
- Stoke Therapeutics shares are trading lower after the company announced the pricing of an upsized $125 million public offering of 5,555,557 common shares at $13.50 per share.Benzinga Newsdesk - Mar 28, 2024, 1:00PM
- Stoke Therapeutics Prices Upsized $125M Public Offering Of 5,555,557 Common Shares At $13.50/ShareBenzinga Newsdesk - Mar 28, 2024, 1:38AM
Wednesday, March 27, 2024
Tuesday, March 26, 2024
- What's Going On With Stoke Therapeutics Stock Tuesday?Adam Eckert - Mar 26, 2024, 4:54PM
- Stoke Therapeutics Announces Proposed Public Offering Of Up To $75M Of Common StockBenzinga Newsdesk - Mar 26, 2024, 4:10PM
- Crude Oil Moves Lower; TD SYNNEX Earnings Top EstimatesAvi Kapoor - Mar 26, 2024, 3:08PM
- Why Westport Fuel Systems Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 26, 2024, 1:45PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Mar 26, 2024, 1:31PM
- Dow Gains 100 Points; McCormick Posts Upbeat ResultsAvi Kapoor - Mar 26, 2024, 12:08PM
- Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In FebruaryAvi Kapoor - Mar 26, 2024, 10:09AM
- Wedbush Maintains Outperform on Stoke Therapeutics, Raises Price Target to $17Benzinga Newsdesk - Mar 26, 2024, 9:36AM
- Stoke Therapeutics' Anti-Epilepsy Drug Candidate Shows Substantial, Sustained Reductions In Seizure Frequency In Pretreated PatientsVandana Singh - Mar 26, 2024, 9:20AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Mar 26, 2024, 9:05AM
- Tesla To $120? Here Are 10 Top Analyst Forecasts For TuesdayAvi Kapoor - Mar 26, 2024, 8:30AM
- Market-Moving News for March 26thBenzinga Newsdesk - Mar 26, 2024, 8:26AM
- Why Stoke Therapeutics Shares Are Trading Higher By Around 70%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 26, 2024, 8:00AM
- Canaccord Genuity Maintains Buy on Stoke Therapeutics, Raises Price Target to $21Benzinga Newsdesk - Mar 26, 2024, 7:04AM
- Stoke Therapeutics shares are trading higher after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.Benzinga Newsdesk - Mar 26, 2024, 6:58AM
- TD Cowen Upgrades Stoke Therapeutics to BuyBenzinga Newsdesk - Mar 26, 2024, 6:18AM
- HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price TargetBenzinga Newsdesk - Mar 26, 2024, 6:13AM
- Needham Maintains Buy on Stoke Therapeutics, Raises Price Target to $22Benzinga Newsdesk - Mar 26, 2024, 5:53AM
Monday, March 25, 2024
- 12 Health Care Stocks Moving In Monday's After-Market SessionBenzinga Insights - Mar 25, 2024, 5:32PM
- Stoke Therapeutics shares are trading higher after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.Benzinga Newsdesk - Mar 25, 2024, 4:47PM
- Stoke Therapeutics Stock Rockets On Phase 1/2a Data: Here's WhyErica Kollmann - Mar 25, 2024, 4:40PM
- Stoke Therapeutics Announces New Data Supporting Potential For STK-001 To Be First Disease-Modifying Medicine For Treatment Of Patients With Dravet SyndromeBenzinga Newsdesk - Mar 25, 2024, 4:04PM
- Stoke Therapeutics Q4 EPS $(0.60) Beats $(0.63) Estimate, Sales $2.80M Miss $3.25M EstimateBenzinga Newsdesk - Mar 25, 2024, 4:03PM
Friday, February 16, 2024
Friday, December 01, 2023
Tuesday, November 21, 2023
Tuesday, November 07, 2023
- Needham Maintains Buy on Stoke Therapeutics, Lowers Price Target to $14Benzinga Newsdesk - Nov 7, 2023, 3:32PM
- As Of September 30, 2023, Stoke Therapeutics Had $214.7M In Cash, Cash Equivalents And Marketable Securities, Anticipated To Fund Operations To The End Of 2025Benzinga Newsdesk - Nov 7, 2023, 7:13AM
- Stoke Therapeutics Q3 EPS $(0.55) Beats $(0.63) Estimate, Sales $3.31M Beat $3.19M EstimateBenzinga Newsdesk - Nov 7, 2023, 7:12AM
Wednesday, October 04, 2023
Tuesday, October 03, 2023
Thursday, September 28, 2023
Tuesday, September 26, 2023
Thursday, September 21, 2023
Wednesday, September 06, 2023
Monday, August 14, 2023
Tuesday, August 08, 2023
- Cantor Fitzgerald Maintains Overweight on Stoke Therapeutics, Lowers Price Target to $14Benzinga Newsdesk - Aug 8, 2023, 1:33PM
- Credit Suisse Reiterates Outperform on Stoke Therapeutics, Maintains $23 Price TargetBenzinga Newsdesk - Aug 8, 2023, 8:17AM
- HC Wainwright & Co. Reiterates Buy on Stoke Therapeutics, Maintains $35 Price TargetBenzinga Newsdesk - Aug 8, 2023, 6:36AM